MetaCap

aTyr Pharma Inc. (ATYR)

NASDAQ: ATYRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.2481-0.0072 (-2.82%)

Market open · Delayed 15 min · as of Oct 9, 3:44 PM ET

ATYR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$24.34M
P/E (TTM)
—
Forward P/E
—
EPS (TTM)
-$0.62
Dividend yield
None
Ex-dividend date
—
52-week range
0.246 – 1.12
Day range
0.246 – 0.2591
Volume / Avg
960.15K / 3.24M
Beta
—
Shares outstanding
98.09M
Next earnings
Nov 5, 2026

52-week range

$0.246$1.12

ATYR stock today

Shares of aTyr Pharma (ATYR) are trading lower on Oct 9 at $0.2481, a drop of 2.82% or $0.0072 per share, versus the S&P 500's 0.61% gain. At this level, ATYR sits near the bottom of its 52-week range of $0.246 to $1.12: 77.8% below the high, set on Oct 10, 2025 and 0.9% above the low. ATYR is down 67.4% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 74.5%.

aTyr Pharma has posted a net loss over the last twelve months (EPS of -$0.62), so its P/E ratio is not meaningful. aTyr Pharma's next earnings report is expected on Nov 5, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About aTyr Pharma

Company profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Headquarters
San Diego, CA
Employees
58
IPO year
2015
Website
atyrpharma.com

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$2.86+1052.76%

  • Strong buy 2
  • Buy 2
  • Hold 5
  • Sell 0
  • Strong sell 0

Target range

Low $1.00High $7.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 5, 2026
EPS estimate
$-0.11

aTyr Pharma peers

Health Care sector
ATYR peer companies
CompanyPrice% ChgMarket capCompare
EVAXEvaxion A/S ADR3.08+0.82%$27.74Mvs ATYR
SCLXScilex Holding Company2.91-1.69%$20.47Mvs ATYR
JSPRJasper Therapeutics Inc.0.5662+1.11%$18.84Mvs ATYR
QNCXQuince Therapeutics Inc.31.43+7.03%$31.96Mvs ATYR
DYAIDyadic International Inc.0.4492+1.08%$18.00Mvs ATYR
ESLAEstrella Immunopharma Inc.0.4099-1.82%$17.83Mvs ATYR
ALGSAligos Therapeutics Inc.5.37+1.13%$33.53Mvs ATYR
CVMCel-Sci Corporation1.91-2.05%$33.59Mvs ATYR

Indexes, lists and sector

aTyr Pharma stock FAQ

What is aTyr Pharma's stock price today?

ATYR last traded at $0.2481 as of Oct 9, 3:44 PM EDT, down 2.82% on the day. Prices are delayed at least 15 minutes.

Does aTyr Pharma pay a dividend?

No. aTyr Pharma does not currently pay a regular cash dividend.

When is aTyr Pharma's next earnings date?

aTyr Pharma is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.11.

Who is aTyr Pharma's CEO?

Dr. Sanjay S. Shukla M.D., M.S. is the chief executive officer of aTyr Pharma Inc., which has about 58 employees.

Has ATYR ever split its stock?

Yes. The most recent ATYR stock split was a 1-for-14 split on Jul 1, 2019.

What is the ATYR 52-week high?

The 52-week high for ATYR is $1.12 and the 52-week low is $0.246. The stock is currently 77.8% below its high.

Compare ATYR